Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2010

01-12-2010 | Research Article

p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells

Authors: Xia Wang, Wei Gong, Haitao Qing, Yan Geng, Xinying Wang, Yongsheng Zhang, Liang Peng, Hongquan Zhang, Bo Jiang

Published in: Tumor Biology | Issue 6/2010

Login to get access

Abstract

p21-activated kinase 5 (PAK5) is a recently identified member of the group B PAK family. The PAK proteins are effectors of the small GTPase Cdc42 and Rac1 and are known to regulate cell motility and activate cell-survival signaling pathways. Especially, the mitochondrial localization of PAK5 is vital to its effects on apoptosis and cell survival. Previously, we demonstrated that PAK5 expression increased significantly during the malignant progression of colorectal carcinoma (CRC) and that PAK5 promoted CRC metastasis by regulating CRC cell adhesion and migration. In the present study, we aim to investigate the role of PAK5 in camptothecin-induced apoptosis and its potential mechanism of action. Our results showed that overexpression of PAK5 inhibited camptothecin-induced apoptosis by inhibiting the activity of caspase-8 in CRC cells. Accordingly, knockdown of PAK5 in LoVo cells resulted in increased apoptosis. Mechanistically, we found that PAK5 directly phosphorylated Bad on serine 112 and indirectly led to phosphorylation of serine 136 via the Akt pathway. In conclusion, our study revealed previously unappreciated inhibitory role of PAK5 in camptothecin-induced apoptosis, thus suggesting PAK5 as a novel therapeutic target in CRC.
Literature
1.
Ching YP, Leong VY, Wong CM, Kung HF. Identification of an autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem. 2003;278:33621–4.CrossRefPubMed
2.
Jaffer ZM, Chernoff J. p21-activated kinases: three more join the Pak. Int J Biochem Cell Biol. 2002;34:713–7.CrossRefPubMed
3.
Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol. 2001;11:220–30.CrossRefPubMed
4.
Parrini MC, Lei M, Harrison SC, Mayer BJ. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell. 2002;9:73–83.CrossRefPubMed
5.
Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999;1:253–9.CrossRefPubMed
6.
Frost JA, Khokhlatchev A, Stippec S, White MA, Cobb MH. Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation. J Biol Chem. 1998;273:28191–8.CrossRefPubMed
7.
Kiosses WB, Daniels RH, Otey C, Bokoch GM, Schwartz MA. A role for p21-activated kinase in endothelial cell migration. J Cell Biol. 1999;147:831–44.CrossRefPubMed
8.
Manser E, Huang H-Y, Loo T-H, Chen XQ, Leung T, Lim L. Expression of constitutively active a-Pak reveals effects of the kinase on actinand focal complexes. Mol Cell Biol. 1997;17:1129–43.PubMed
9.
Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol. 1999;145:837–49.CrossRefPubMed
10.
Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7:202–10.CrossRefPubMed
11.
Rudel T, Zenke FT, Chuang T-H, Bokoch GM. p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol. 1998;160:7–11.PubMed
12.
Lee N, MacDonald H, Reinhard C, Halenbeck R, Roulston A, Shi T, et al. Activation of hPAK65 by caspase cleavage induces some of the morphological and biochemical changes of apoptosis. Proc Natl Acad Sci USA. 1997;94:13642–7.CrossRefPubMed
13.
Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science. 1997;276:1571–4.CrossRefPubMed
14.
Walter BN, Huang Z, Jakobi R, Tuazon PT, Alnemri ES, Litwack G, et al. Cleavage and activation of p21-activated protein kinase gamma-PAK by CPP32 (caspase 3). Effects of autophosphorylation on activity. J Biol Chem. 1998;273:28733–9.CrossRefPubMed
15.
Daniels RH, Bokoch GM. p21-activated protein kinase: acrucial component of morphological signaling? Trends Biochem Sci. 1999;24:350–5.CrossRefPubMed
16.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell. 1997;91:231–41.CrossRefPubMed
17.
Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang H-G, Reed JC, et al. p21-activated kinase 1 (PAK1) phosphorylates the death agonist BAD and protects cells from apoptosis. Mol Cell Biol. 2000;20:453–61.CrossRefPubMed
18.
Gnesutta N, Qu J, Minden AG. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem. 2001;276:14414–9.CrossRefPubMed
19.
Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E, et al. Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II sub-family that is predominantly expressed in brain. Oncogene. 2002;21:3939–48.CrossRefPubMed
20.
Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-activated kinase 5(Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 2003;23:5526–39.CrossRefPubMed
21.
Cotteret S, Chernoff J. Nucleocytoplasmic shuttling of pak5 regulates its antiapoptotic properties. Mol Cell Biol. 2006;26:3215–30.CrossRefPubMed
22.
Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA. p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem. 2008;105:167–75.CrossRefPubMed
23.
Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B, et al. P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer. 2009;125:548–55.CrossRefPubMed
24.
Jin S, Zhuo Y, Guo W, Field J. p21-activated kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial local-ization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem. 2005;280:24698–705.CrossRefPubMed
25.
Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003;63:8791–812.PubMed
26.
Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002;21:3704–14.CrossRefPubMed
27.
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–5.CrossRefPubMed
28.
Li H, Zhu H, Xy C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Cell. 1998;94:491–501.CrossRefPubMed
29.
Bradley EW, Ruan MM, Oursler MJ. PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival. J Cell Physiol. 2008;217:752–8.CrossRefPubMed
30.
Liang QL, Wang BR, Li GH. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B. 2009;10:675–82.CrossRefPubMed
31.
Tang Y, Zhou H, Chen A, Pittman RN, Field J. The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem. 2000;275:9106–9.CrossRefPubMed
Metadata
Title
p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells
Authors
Xia Wang
Wei Gong
Haitao Qing
Yan Geng
Xinying Wang
Yongsheng Zhang
Liang Peng
Hongquan Zhang
Bo Jiang
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0071-3

Other articles of this Issue 6/2010

Tumor Biology 6/2010 Go to the issue

Research Article

The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer

Research Article

PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac

Research Article

CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma

Research Article

Reduced Walker 256 carcinosarcoma growth in vasopressin-deficient Brattleboro rats

Research Article

Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma

Research Article

RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits